156a3def-5866-4be4-ad0b-61b957d5b6eb
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- IL6_JAK_STAT3_SIGNALING+0.500
- ANGIOGENESIS+0.400
- TGF_BETA_SIGNALING+0.400
- ALLOGRAFT_REJECTION+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
- MITOTIC_SPINDLE+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.700
- FATTY_ACID_METABOLISM-0.500
- MTORC1_SIGNALING-0.500
- MYC_TARGETS_V2-0.500
- ADIPOGENESIS-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- MYC_TARGETS_V1-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- BILE_ACID_METABOLISM-0.300
- PANCREAS_BETA_CELLS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_12_0175_A5_S64 | — | D | 0.865 |
| 2 | 66e5440a-6b08-43cc-b007-82ac3f5221d1 | — | — | 0.841 |
| 3 | TCGA-A7-A26F-01B-04R-A22O-07 | — | D | 0.830 |
| 4 | 1ae8df2d-8c7c-474d-9208-ea63784edc90 | — | — | 0.823 |
| 5 | TCGA-56-8628-01A-11R-2403-07 | — | cohortSQ1 | 0.822 |
| 6 | SRR10900585 | — | — | 0.822 |
| 7 | SRR25043620 | — | — | 0.818 |
| 8 | C3N-03233 | — | cohortA1 | 0.817 |
| 9 | 5943bf89-bad2-4461-8d80-7f9481810257 | — | — | 0.817 |
| 10 | 1fd89d3a-5991-4bfb-b27f-66b5f2a289d8 | — | — | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |